Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Français de Pneumo-Cancérologie Study

This publication has 12 references indexed in Scilit:

• Paclitaxel (P) in combination with carboplatin (C) in the treatment of SCLC patients (a phase II study)
  Lung Cancer, 2000
• Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non–Cross-Resistant Schedule
  Journal of Clinical Oncology, 1999
• Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
  Journal of Clinical Oncology, 1997
• Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group study.
  Journal of Clinical Oncology, 1995
• Justification for Evaluating New Anticancer Drugs in Selected Untreated Patients With Extensive-Stage Small-Cell Lung Cancer: An Eastern Cooperative Oncology Group Randomized Study
  JNCI Journal of the National Cancer Institute, 1992
• Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
  Journal of Clinical Oncology, 1992
• Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1991
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
  Journal of Clinical Oncology, 1989
• Reporting results of cancer treatment
  Cancer, 1981
• Prediction of Creatinine Clearance from Serum Creatinine
  Nephron, 1976